ClinicalTrials.gg

Program

LB-102

Also written as “LB-102 (50 mg tablet)” and “LB-102 (100 mg tablet)”.

Its studies are mostly in Schizophrenia, led by LB Pharmaceuticals.

Furthest: phase 3, since Dec 26, 20256 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LB Pharmaceuticals63 open or runningphase 3since Dec 26, 2025Nov 26, 2019Jun 2027phase 3 · NCT07363577

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2019First study: phase 1 study in SchizophreniaFirst studyNCT04187560 · 64 enrolled · United States
  2. Oct 6, 2020Phase 1 study in SchizophreniaNCT04588129 · 16 enrolled · United States
  3. Dec 12, 2023Phase 2 study in SchizophreniaNCT06179108 · 359 enrolled · United States
  4. Dec 26, 2025Phase 2 study in Bipolar I DisorderNCT07494305 · 320 planned · United States
  5. Dec 26, 20252 phase 3 studies in SchizophreniaPhase 3 reachedNCT07369154, NCT07363577

Ahead

  1. Jun 2027Primary completion: phase 3 study in SchizophreniaNCT07363577
  2. Feb 2028Primary completion: phase 2 study in Bipolar I DisorderNCT07494305
  3. Dec 2028Primary completion: phase 3 study in SchizophreniaNCT07369154

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07494305Bipolar I Disorder · United States2RecruitingFeb 2028320
NCT07369154Schizophrenia · United States3RecruitingDec 2028900
NCT07363577Schizophrenia · United States3RecruitingJun 2027456
NCT06179108Schizophrenia · United States2CompletedDec 4, 2024359
NCT04588129Schizophrenia · United States1CompletedSep 17, 202116
NCT04187560Schizophrenia · United States1CompletedJul 1, 202064

How it is read

Names in the registry

  • “LB-102”, 5 entries
  • “LB-102 (50 mg tablet)”, 1 entry
  • “LB-102 (100 mg tablet)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.